Weekly recap: remibrutinib Phase III success, ALS program halt

Recap highlights remibrutinib Phase III success and a positive CHMP opinion for Cosentyx alongside later-stage failures and safety suspensions, plus investor calls for board changes and reported expansion into DLL3 CAR-T rights.